Objectives: Human enterovirus 71 (EV-71), a member of the Enterovirus genus, constitutes a major public health issue in the Asia-Pacific region, where it is associated with several severe neurological complications. There is currently no effective vaccine or antiviral against EV-71. The aim of this study was to determine whether the six amino acid peptide LVLQTM, which was previously shown to inhibit human rhinovirus (HRV) 2A protease (2A pro ) activity in vitro and HRV replication in vivo in mice, could be of more general use against enteroviruses and more particularly against EV-71.
Introduction
Human enterovirus 71 (EV-71), a member of the Enterovirus genus, is a causative agent of hand, foot and mouth disease, aseptic meningitis, brainstem encephalitis and poliomyelitis-like acute flaccid paralysis.
1 EV-71 is the most pathogenic non-polio enterovirus in the Asia-Pacific region, where several outbreaks have been reported. The largest EV-71 epidemic so far occurred in 1998 in Taiwan, where 1.5 million people and .100000 children were infected. Among them, 405 severe cases of neurological and cardiopulmonary complications were described, of which 78 were fatal. 1 Moreover, the latest large Asian epidemic was in China in 2008, where 490 000 infections and 126 deaths in children were reported. 2 There is no effective vaccine against EV-71 available on the market, despite the investigation of various types of vaccines, including inactivated whole virus, live-attenuated, subviral particle and DNA vaccines. 3, 4 In addition, several antiviral strategies have been employed, including compound library screening and revisiting of some antivirals developed against poliovirus and rhinovirus, but none of them has been approved yet. The lack of vaccine or antiviral options against EV-71 remains a worrying situation, as EV-71 has been found to circulate endemically. Thus, the aim of this study was to describe a new inhibitor of EV-71 infection.
We previously showed that some peptide ligands that were selected from a human placenta cDNA library by the yeast twohybrid procedure inhibited the activity of the human rhinovirus (another member of the Enterovirus genus) 2A protease (2A   pro   ) by docking into the active site of the enzyme. 5 Among them, the dominant peptide LVLQTM was also shown to inhibit subsequent viral replication in vitro in A549 cells and in vivo in mice, and could therefore be an interesting lead compound for a therapeutic agent against rhinoviruses. In the present study, we demonstrated that the LVLQTM peptide is also a strong inhibitor of EV-71 2A pro cleavage activity as well as EV-71 replication, opening new prospects in the development of anti-EV-71 drugs.
Materials and methods
Most protocols used in this study have already been described in detail in Falah et al. 5 Specific methods are detailed in Supplementary data (available at JAC Online).
Results and discussion
Expression and purification of EV-71 2A pro Production of soluble and active EV-71 2A pro in the cytoplasm of Escherichia coli was achieved through the Staby plasmid system (Eurogentec). Purification of the 2A protein from the cell extract was achieved by metal-chelate affinity chromatography followed by size-exclusion chromatography (SEC). The SEC elution profile depicted in Figure 1 (a) shows that EV-71 2A pro (peak D1) was purified to .95% purity, as estimated by SDS-PAGE analysis. However, the enzyme presented very abnormal chromatographic behaviour, since it was eluted very late from the SEC column together with the salt, which made it impossible to accurately determine its molecular weight using column calibration. To resolve this problem, the combined technology SEC-multiangle light scattering (SEC-MALS) was used. This analysis, presented in Figure 1 (b), revealed that 2A pro , which eluted in a main peak from 17.0 to 18.8 mL, had a calculated molecular mass of 17.7 kDa and thus behaved essentially as a monomer. Noticeably, this monomeric organization is very similar to that of other 2A pro , as previously described for Coxsackie virus B4 (CVB4) and human rhinovirus B14 (HRV-B14) 2A
pro , which also behave as monomers.
-8
The LVLQTM peptide is a pseudosubstrate of EV-71 2A pro
The ability of the LVLQTM peptide to act as a pseudosubstrate of EV-71 2A pro was evaluated in vitro in the Protease-Glo TM Assay (Promega). In this assay, the LVLQTM-G peptide was inserted in frame into the linker region of the GloSensor TM luciferase. This sequence was chosen to reconstruct a potent site of cleavage by the protease, with LVLQTM corresponding to P1-P6 residues on the N-terminal side of the scissile bond and glycine corresponding to the P1 ′ residue, as this amino acid is found in the equivalent position in the authentic cis-cleavage site of the EV-71 polyprotein. As shown in Figure 1 (c), significant activation of the luciferase containing the LVLQTM-G sequence was detected when incubation was performed in the presence of EV-71 2A
pro . This cleavage was specific, since no luminescence was measured when using a luciferase protein containing the peptide sequence ENLYFQ-S, which was only cut by the TEV protease (positive control).
Measuring LVLQTM peptide binding to EV-71 2A pro by isothermal titration calorimetry
We used isothermal titration calorimetry to investigate the interaction between EV-71 2A pro and the LVLQTM peptide ( Figure 1d ). The results showed that the binding was exothermic and analysis of the data yielded a dissociation constant (K d ) of 9.6 mM. Concerning thermodynamic parameters, binding of LVLQTM to EV-71 2A pro was associated with favourable entropy (DS¼ 19.7 cal/mol/deg, i.e. TDS¼ 5.8 kcal/mol) and favourable enthalpy (DH ¼ 2956 cal/mol). The favourable enthalpy indicated that the peptide established tight interactions through hydrogen bonds and Van der Waals contacts, and that these interactions were strong enough to compensate for the unfavourable enthalpy associated with desolvation. On the other hand, the highly favourable entropy showed that the binding mainly involved hydrophobic interactions and was consistent with the displacement of water molecules from the active site and/or peptide hydration shell. Moreover, this high TDS value, indicating that the interaction between EV-71 2A pro and the LVLQTM peptide was predominantly entropic, might also reflect low conformational entropy change, as a consequence of the loss of conformational degrees of freedom of both the drug molecule and the protein molecule upon binding.
Taken together, these results demonstrated that the LVLQTM peptide exhibits an overall conformation that fits well with the substrate-binding pocket of EV-71 2A pro and may thus represent a potent inhibitor of this enzyme.
LVLQTM peptide inhibits eIF4G-cleavage activity of EV-71 2A pro We then investigated the effects of the LVLQTM peptide on 2A pro activity in a cellular system. Based on our previous results, the benzyloxycarbonyl-LVLQTM-fluoromethylketone (z-LVLQTM-fmk) was preferably used in an in cellulo cleavage assay that relied on the ability of the EV-71 2A pro to hydrolyse the initiation factor of translation, eIF4G. 7 The results depicted in Figure 2 (a) indicated that EV-71 2A pro -induced inhibition of cap-R-luciferase activity in the presence of the control peptide z-FA-fmk was completely dismissed in the presence of z-LVLQTM-fmk. Similarly, EV-71 2A pro -induced enhancement of internal ribosome entry site (IRES)-R-luciferase activity was inhibited when cells were treated with z-LVLQTM-fmk. Altogether, these results demonstrated that z-LVLQTM-fmk specifically inhibited EV-71 2A pro activity in HeLa cells.
z-LVLQTM-fmk peptide inhibits EV-71 replication
To investigate whether the z-LVLQTM-fmk peptide could inhibit EV-71 replication, HeLa cells were infected with EV-71 (multiplicity of infection ¼ 1) and treated with 200 mM z-FA-fmk or z-LVLQTM-fmk at different times before and after infection. Total virus titres were determined 24 h post-infection. As indicated in Figure 2(b) , the presence of z-LVLQTM-fmk reduced virus multiplication by .50-fold when cells were infected and treated at the same time. Noticeably, delayed administration of the peptide at 2 and 4 h post-infection had a more Falah et al. In summary, the LVLQTM peptide, which was previously characterized as a new inhibitor of HRV 2A pro , also impairs EV-71 2A pro activity. These results are consistent with the comparison of the sequences of these proteases, which revealed minor differences in the nature of their substrate-binding pocket residues. 5 
LVLQTM peptide represents a potential inhibitor of multiple EV-71 2A pro variants
The 2A pro sequences from 40 EV-71 strains were compared to evaluate whether the LVLQTM peptide could be of general use against different EV-71 genotypes. Genotyping of EV-71 has so far been based on structural genes VP1 and VP4. Recently, Chan et al. 9 proposed a new classification into four genotypes, A-D, based on EV-71 complete genomes (taking into account 2A pro variants). Point mutations occur at 22 positions along the 2A pro sequence (Figure 2c and Figure S1 available as Supplementary data at JAC Online). More than half are located on the surface of the protease and are unlikely to interfere with LVLQTM binding. Five mutations are buried and only mutation S125P found for the SHZH98 strain may induce local or longrange conformational rearrangement. More interestingly, four mutations occur at particular positions corresponding to substrate-binding pocket residues defined for HRV-A2 2A pro . 5 In
HRV-A2
HRV-A2
EV Falah et al. particular, the S5 Asn129 residue is extremely conserved among nearly all EV-71 serotypes analysed in this study and is consistent with the presence of an aspartate in HRV-A2 or a glutamate in EV-6 and poliovirus-1. Only EV-71 strain BrCr displays a serine at this position. The shorter side chain of serine compared with that of aspartate or asparagine likely reflects some flexibility of the substrate at P5. This could suggest a lesser affinity of this strain for the LVLQTM peptide, as previously shown for HRV-B14 displaying also a serine at position 129. 5 The apolar depression defining S4 is maintained, as mutations I82V and V84G/I are both conservative. Finally, mutation P107S in strain MS742387 occurs at S1 in a very well conserved stretch of residues. HRV-B14 2A pro , which also displays a mutation at this position (proline to leucine), is still inhibited by LVLQTM, suggesting that the peptide nonetheless inhibits strain MS742387.
The general conclusion from these analyses supports the view that the peptide inhibitor LVLQTM may interact with a large spectrum of EV-71 2A pro s, especially from subgenotypes B4, B5, C1, C2, C5 and D currently circulating in the world and associated with severe CNS infection of young children.
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